FDA Approves Orzeyful for Narcolepsy Type 1 Treatment
1 report, 1 independent
Updated Thu 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The US Food and Drug Administration approved Orzeyful, an orexin agonist designed to address the root cause of Narcolepsy Type 1 (NT1). Orzeyful is manufactured by Takeda and is the first therapy designed to restore signaling through the orexin pathway.
From sleepreviewmag.com
Why it matters
The approval represents a significant advance in sleep medicine. Orexin regulates rapid eye movement sleep and muscle tone, and NT1 involves a loss of orexin-producing neurons in the hypothalamus, which prevents the brain from maintaining a steady level of wakefulness.
From sleepreviewmag.com